| scholarly article | Q13442814 |
| P2093 | author name string | J M Entenza | |
| P Moreillon | |||
| M Giddey | |||
| J Vouillamoz | |||
| P Majcherczyk | |||
| T R Veloso | |||
| P2860 | cites work | Infective endocarditis. | Q53905921 |
| The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. | Q54105049 | ||
| Peptidoglycan composition in heterogeneous Tn551 mutants of a methicillin-resistant Staphylococcus aureus strain | Q54268348 | ||
| Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. | Q54322604 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus | Q68198941 | ||
| Digestion of Streptococcus pneumoniae cell walls with its major peptidoglycan hydrolase releases branched stem peptides carrying proinflammatory activity | Q77353720 | ||
| The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin | Q80124611 | ||
| An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus | Q83230645 | ||
| Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus | Q83583751 | ||
| In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci | Q24550612 | ||
| Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications | Q24646677 | ||
| Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus | Q24679159 | ||
| Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence | Q33371390 | ||
| An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci | Q33943929 | ||
| Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility | Q33962676 | ||
| Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin | Q33977223 | ||
| Vancomycin and oxacillin synergy for methicillin-resistant staphylococci | Q33979572 | ||
| Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics | Q33979939 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae | Q34624359 | ||
| PBP 2a mutations producing very-high-level resistance to beta-lactams | Q35547377 | ||
| Vancomycin pharmacokinetics in normal and morbidly obese subjects | Q35675005 | ||
| Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats | Q35823261 | ||
| Beta-lactams against methicillin-resistant Staphylococcus aureus | Q36226697 | ||
| Natural history of aortic valve endocarditis in rats | Q36328909 | ||
| Anti-MRSA beta-lactams in development | Q36561331 | ||
| Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy | Q36763997 | ||
| Management of methicillin-resistant Staphylococcus aureus bacteremia | Q37156709 | ||
| Management of methicillin-resistant Staphylococcus aureus infections | Q37416330 | ||
| BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins | Q39470055 | ||
| Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin | Q39476999 | ||
| In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains | Q39537168 | ||
| BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | Q39650937 | ||
| Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers | Q40967997 | ||
| Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers | Q40968003 | ||
| Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus | Q41092910 | ||
| Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography | Q41265449 | ||
| Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus | Q42027484 | ||
| Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. | Q42112490 | ||
| In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA) | Q42905521 | ||
| Peptidoglycan cross-linking in Staphylococcus aureus. An apparent random polymerisation process | Q44252770 | ||
| False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods | Q44826290 | ||
| Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. | Q46667726 | ||
| Daptomycin in the treatment of bacteremia | Q46974833 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| vancomycin | Q424027 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 3977-3984 | |
| P577 | publication date | 2011-07-05 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus | |
| P478 | volume | 55 |
| Q28085517 | Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia |
| Q34433342 | Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia |
| Q92522516 | Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial |
| Q92304823 | Ceftobripole: Experience in staphylococcal bacteremia |
| Q34989360 | Combination of alpha-melanocyte stimulating hormone with conventional antibiotics against methicillin resistant Staphylococcus aureus |
| Q36018587 | Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection model |
| Q37546679 | Rapid detection of Staphylococcus aureus strains with reduced susceptibility to vancomycin by isothermal microcalorimetry |
| Q35806369 | Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus |
Search more.